Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 245-254

  Wentrup, Andreas ^a   Oertel, Wolfgang H ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alzheimer's disease; Dementia; Patch; Rivastigmine

Indexed keywords

CYTOCHROME P450; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; COST CONTROL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; HEADACHE; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; LOW DRUG DOSE; NAUSEA; QUALITY OF LIFE; SIDE EFFECT; SKIN IRRITATION; VOMITING; WEIGHT REDUCTION;

EID: 77953660035     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Blesa R, Ballard C, Orgogozo JM, et al. 2007. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology, 69(4 Suppl 1):S23-8. (Pubitemid 47205656)
2. Corey-Bloom J, Anand R, Veach JA. 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartate), a new acetylcholinesterase inhibitor in patients with mild to moderate severe Alzheimer's disease. Int J Geriatr Psychopharmacol, (1):55-65. (Pubitemid 28323228)
3. Corrigan JD, Hinkeldey NS. 1987. Relationships between parts A and B of the Trail Making Test. J Clin Psychol, 43:402-409
4. Crisby M, Carlson LA, Winblad B. 2002. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord, 16:131-136 (Pubitemid 35001087)
5. Cummings J, Winblad B. 2007. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother, 7:1457-1463 (Pubitemid 350106826)
6. Cummings JL. 2004. Alzheimer's disease. N Engl J Med, 351:56-67.
7. Darvesh S, Walsh R, Kumar R, et al. 2003. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord, 17:117-126 (Pubitemid 36736847)
8. Dewachter I, Van Leuven F. 2002. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol, 1:409-416 (Pubitemid 37159151)
9. Dodart JC, Bales KR, Gannon KS, et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci, 5:452-457
10. Dodel RC, Hampel H, Du Y. 2003. Immunotherapy for Alzheimer's disease. Lancet Neurol, 2:215-220
11. Fabbrini G, Brotchie JM, Grandas F, et al. 2007. Levodopa-induced dyskinesias. Mov Disord, 22:1379-89; quiz 523.
12. Farlow M, Anand R, Messina J Jr, et al. 2000. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol, 44:236-241
13. Farlow MR, Cummings JL. 2007. Effective pharmacologic management of Alzheimer's disease. Am J Med, 120:388-397 (Pubitemid 46627453)
14. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12:189-198
15. Galasko D, Bennett D, Sano M, et al. 1997. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord, 11(Suppl 2):S33-9.
16. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353-356 (Pubitemid 34790756)
17. Hossain M, Jhee SS, Shiovitz T, et al. 2002. Estimation of the absolute bio-availability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet, 41:225-234 (Pubitemid 34415840)
18. in t' Veld BA, Ruitenberg A, Hofman A, et al. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med, 345:1515-1521
19. Inglis F. 2002. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl, (127):45-63. (Pubitemid 34778530)
20. Institute for Quality and Efficiency in Health Care. 2007. Cholinesterase inhibitors in Alzheimer's disease.
21. Jann MW, Shirley KL, Small GW. 2002. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet, 41:719-739 (Pubitemid 34948194)
22. Lefevre G, Sedek G, Huang HL, et al. 2007. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol, 47:471-478 (Pubitemid 46465956)
23. Lefevre G, Sedek G, Jhee SS, et al. 2008. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther, 83:106-114
24. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 47:425-432 (Pubitemid 26324038)
25. Mercier F, Lefevre G, Huang HL, et al. 2007. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin, 23:3199-3204
26. Morgan D, Diamond DM, Gottschall PE, et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408:982-985 (Pubitemid 32101645)
27. NICE. 2007. Donezepil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). NICE technology appraisal guidance 111 (amended).
28. Novartis. 2007. http://wwwpharmaus novartiscom/product/pi/pdf/ exelonpatchpdf.
29. Oertel W, Ross JS, Eggert K, et al. 2007. Rationale for transdermal drug administration in Alzheimer disease. Neurology, 69(4 Suppl 1):S4-9. (Pubitemid 47205653)
30. Orgogozo JM, Gilman S, Dartigues JF, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61(1):46-54. (Pubitemid 36818745)
31. Permanne B, Adessi C, Fraga S, et al. 2002. Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J Neural Transm Suppl, (62):293-301. (Pubitemid 37046673)
32. Perry EK, Tomlinson BE, Blessed G, et al. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J, 2:1457-1459 (Pubitemid 9061468)
33. Polinsky RJ. 1998. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther, 20:634-647 (Pubitemid 28421485)
34. Priano L, Gasco MR, Mauro A. 2006. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging, 23:357-375 (Pubitemid 44050424)
35. Puglielli L, Tanzi RE, Kovacs DM. 2003. Alzheimer's disease: the cholesterol connection. Nat Neurosci, 6:345-351
36. Raskind MA, Peskind ER, Truyen L, et al. 2004. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol, 61:252-256 (Pubitemid 38197559)
37. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry, 141:1356-1364
38. Rosler M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Bmj, 318:633-638 (Pubitemid 29192055)
39. Scarpini E, Scheltens P, Feldman H. 2003. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol, 2:539-547 (Pubitemid 36994993)
40. Schenk D, Barbour R, Dunn W, et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400:173-177 (Pubitemid 29327547)
41. Schneider LS, Olin JT. 1996. Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr, 8:277-88; discussion 88-90.
42. Schwabe U, Paffrath D. 2007. Arzneiverordnungs-Report 2007. Heidelberg: Springer.
43. Small G, Dubois B. 2007. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin, 23:2705-2713 (Pubitemid 350146408)
44. Small GW, Kaufer D, Mendiondo MS, et al. 2005. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract, 59:473-477 (Pubitemid 40467894)
45. Soto C, Saborio GP, Permanne B. 2000. Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta Neurol Scand Suppl, 176:90-95 (Pubitemid 32156176)
46. Summers WK, Majovski LV, Marsh GM, et al. 1986. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med, 315:1241-1245 (Pubitemid 17049681)
47. US Food and Drug Administration. 2008. http://wwwfdagov/consumer/updates/ exelonpatch080307html.
48. van Gool WA, Aisen PS, Eikelenboom P. 2003. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol, 250:788-792 (Pubitemid 36898108)
49. Watson YI, Arfken CL, Birge SJ. 1993. Clock completion: an objective screening test for dementia. J Am Geriatr Soc, 41:1235-1240
50. Watts RL, Jankovic J, Waters C, et al. 2007. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology, 68:272-276 (Pubitemid 46148338)
51. Weggen S, Eriksen JL, Das P, et al. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414:212-216 (Pubitemid 33051236)
52. Winblad B, Cummings J, Andreasen N, et al. 2007a. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry, 22:456-467 (Pubitemid 46831690)
53. Winblad B, Grossberg G, Frolich L, et al. 2007b. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology, 69(4 Suppl 1):S14-22. (Pubitemid 47205655)
54. Winblad B, Kawata AK, Beusterien KM, et al.2007c. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry, 22:485-491
55. Xie W, Stribley JA, Chatonnet A, et al. 2000. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther, 293:896-902. (Pubitemid 30417856)
56. Yang LP, Keating GM. 2007. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. CNS Drugs, 21:957-965 (Pubitemid 47557109)